Manzardo S, Falcone A, Pinzetta A, Ieva G, Coppi G
Research Centre, Poli Industria Chimica S.p.A., Milan, Italy.
Arzneimittelforschung. 1994 Dec;44(12A):1441-7.
Pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) is a new biological response modifier. General pharmacology and interactions with some drugs were tested. The drug, at doses of 200 mg/kg i.p. and 400 mg/kg p.o., did not affect the normal behaviour, did not modify the responses to stimulation of autonomic nervous system or central nervous system. Pidotimod did not display any cardiovascular or respiratory effect up to 125 mg/kg i.v. in 3 animal species. The drug did not show antimicrobial or antifungal activities nor interact with some of the most common therapeutics (antibiotics, tolbutamide, pentobarbital, antihypertensives, chlorothiazide, warfarin, non-steroidal antiinflammatory agents). On the basis of these results pidotimod shows a safe profile; moreover it does not interact with many therapeutic agents.
匹多莫德（(R)-3-[(S)-(5-氧代-2-吡咯烷基)羰基]-噻唑烷-4-羧酸，PGT/1A，CAS 121808-62-6）是一种新型生物反应调节剂。对其进行了一般药理学研究以及与某些药物的相互作用研究。该药物腹腔注射剂量为200 mg/kg和口服剂量为400 mg/kg时，不影响正常行为，不改变对自主神经系统或中枢神经系统刺激的反应。在3种动物中，静脉注射高达125 mg/kg的匹多莫德未显示出任何心血管或呼吸作用。该药物未表现出抗菌或抗真菌活性，也不与一些最常用的治疗药物（抗生素、甲苯磺丁脲、戊巴比妥、抗高血压药、氯噻嗪、华法林、非甾体抗炎药）相互作用。基于这些结果，匹多莫德显示出安全的特性；此外，它不与许多治疗药物相互作用。
